| Year |
Citation |
Score |
| 2017 |
Silva AS, Silva MD, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, et al. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Research. PMID 28400475 DOI: 10.1158/0008-5472.Can-17-0502 |
0.324 |
|
| 2015 |
Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. European Journal of Haematology. PMID 25600676 DOI: 10.1111/Ejh.12509 |
0.318 |
|
| 2014 |
Rollison DE, Shain KH, Lee J, Hampras SS, Fisher K, Al Ali NH, Padron E, Lancet JE, Olesnyckyj M, Kenvin L, Knight RD, Dalton W, List AF, Komrokji R. Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide Blood. 124: 413-413. DOI: 10.1182/Blood.V124.21.413.413 |
0.305 |
|
| 2013 |
Tao J, Lwin T, Zhao X, Shah B, Zhang L, Moscinski L, Dalton W, Sotomayor EM, Tao J. Abstract 4944: Combined treatment of BTK and PI3K inhibitors synergistically disrupts BCR-signaling, overcomes microenviroment-mediated survival and drug resistance in mantle cell lymphoma. Cancer Research. 73: 4944-4944. DOI: 10.1158/1538-7445.Am2013-4944 |
0.352 |
|
| 2012 |
Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, et al. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 120: 4513-6. PMID 23018640 DOI: 10.1182/Blood-2012-05-426924 |
0.31 |
|
| 2012 |
Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, ... ... Dalton W, et al. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology. 157: 553-63. PMID 22449149 DOI: 10.1111/J.1365-2141.2012.09099.X |
0.346 |
|
| 2012 |
Alsina M, Baz R, Shain KH, Ochoa L, Nishihori T, Sullivan DM, Yue B, Kim J, Dalton W. Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease Blood. 120: 4071-4071. DOI: 10.1182/Blood.V120.21.4071.4071 |
0.334 |
|
| 2012 |
Baz R, Shain KH, Alsina M, Nardelli LA, Nishihori T, Ochoa L, Martin T, Jagannath S, Dalton W, Sullivan DM. Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort Blood. 120: 4062-4062. DOI: 10.1182/Blood.V120.21.4062.4062 |
0.337 |
|
| 2012 |
Baz R, Alsina M, Shain KH, Paleveda J, Hillgruber N, Finley-Oliver E, Ochoa L, Nishihori T, Dalton W, Sullivan D. Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma Blood. 120: 4060-4060. DOI: 10.1182/Blood.V120.21.4060.4060 |
0.33 |
|
| 2012 |
Fang B, Xiang Y, Mirza S, Remily-Wood E, Mathews L, Dalton W, Shain K, Koomen JM. Abstract 4809: Elucidating acquired drug resistance in multiple myeloma using expression proteomics and phosphorylation profiling Cancer Research. 72: 4809-4809. DOI: 10.1158/1538-7445.Am2012-4809 |
0.327 |
|
| 2011 |
Nong L, Mathews L, Meads MB, Dalton W, Shain KH. Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines Blood. 118: 2922-2922. DOI: 10.1182/Blood.V118.21.2922.2922 |
0.363 |
|
| 2010 |
Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. European Journal of Haematology. 84: 212-22. PMID 19922463 DOI: 10.1111/J.1600-0609.2009.01381.X |
0.303 |
|
| 2009 |
Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, ... ... Dalton W, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5713-9. PMID 19786667 DOI: 10.1200/Jco.2009.22.2679 |
0.322 |
|
| 2008 |
Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. Journal of Immunology (Baltimore, Md. : 1950). 180: 1545-55. PMID 18209050 DOI: 10.4049/Jimmunol.180.3.1545 |
0.322 |
|
| 2008 |
Perez L, Parquet N, Anasetti C, Dalton W. Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma. Blood. 112: 1665-1665. DOI: 10.1182/Blood.V112.11.1665.1665 |
0.336 |
|
| 2008 |
Alsina M, Alekshun T, McIsaac-Simonelli C, Kharfan-Dabaja M, Dalton W, Djulbegovic B, Fernandez H, Sullivan D, Ayala E, Field T, Garrett D, Janssen W, Maddox B, Perez L, Kettner D, et al. 184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL) Biology of Blood and Marrow Transplantation. 14: 68. DOI: 10.1182/Blood.V110.11.5131.5131 |
0.359 |
|
| 2007 |
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, ... ... Dalton W, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 110: 3557-60. PMID 17690257 DOI: 10.1182/Blood-2006-08-036947 |
0.306 |
|
| 2007 |
Sullivan D, Alsina M, Anasetti C, Field T, Kharfan-Dabaja M, Fernandez H, Dalton W, Ayala E, Raychaudhuri J, Perez L, Perkins J, Schell M, McIsaac C, Maddox B, Gump J, et al. Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM). Blood. 110: 943-943. DOI: 10.1182/Blood.V110.11.943.943 |
0.316 |
|
| 2007 |
Perez LE, Parquet N, Molisano M, Shain K, Alsina M, Anasetti C, Dalton W. Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis. Blood. 110: 3521-3521. DOI: 10.1182/Blood.V110.11.3521.3521 |
0.327 |
|
| 2006 |
Perez L, Parquet N, Nimmanapalli R, Alsina M, Dalton W, Anasetti C. Microenvironment confers resistance to TRAIL mediated apoptosis Biology of Blood and Marrow Transplantation. 12: 3. DOI: 10.1182/Blood.V106.11.2489.2489 |
0.345 |
|
| 2005 |
Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-66. PMID 15728126 DOI: 10.1182/Blood-2004-11-4307 |
0.318 |
|
| 2004 |
Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, ... ... Dalton W, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clinic Proceedings. 79: 875-82. PMID 15244383 DOI: 10.4065/79.7.875 |
0.323 |
|
| 2004 |
Parquet N, Nimmanapalli R, Anasetti C, Alsina M, Dalton W, Perez LE. Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR). Blood. 104: 2459-2459. DOI: 10.1182/Blood.V104.11.2459.2459 |
0.331 |
|
| 2003 |
Alsina M, Wilson E, Belle N, Gerbino E, Overton R, Sullivan D, Djulbegovic B, Fonseca R, Dalton W, Sebti S. Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma European Journal of Haematology. 70: 269-269. DOI: 10.1034/J.1600-0609.2003.11213.X |
0.301 |
|
| 2001 |
Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 15: 1232-9. PMID 11480565 DOI: 10.1038/Sj.Leu.2402179 |
0.338 |
|
| 2000 |
Sullivan D, Dalton W, Djulbegovic R, Fields K, Field T, Goldstein S, Partyka J, Perkins J, Janssen W, Lush R, Gump J, Valkov N, McIsaac C. A phase i study of high-dose melphalan + topotecan + VP-16 phosphate (Mtv) Followed by autologous stem cell rescue in multiple myeloma Experimental Hematology. 28: 110. DOI: 10.1016/S0301-472X(00)00428-8 |
0.321 |
|
| 2000 |
Huang M, Catlett-Falcone R, Burdelya L, Landowski T, Oshiro M, Moscinski L, Loughran T, Saba H, Sullivan D, Yu H, Dalton W, Jove R. Constitutive activation of stat signaling in myeloid leukemia cells is associated with resistance to apoptosis Experimental Hematology. 28: 106. DOI: 10.1016/S0301-472X(00)00415-X |
0.307 |
|
| 2000 |
Hazlehurst L, Buyuksal I, Laughrin T, Dalton W, Laughrin ibT. Adhesion of 8226 cells to fibronectin via β1 integrins upregulates P27 levels and contributes to cell adhesion mediated drug resistance (Cam-dr) Experimental Hematology. 28: 76. DOI: 10.1016/S0301-472X(00)00324-6 |
0.306 |
|
| 1995 |
Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Molecular Aspects of Medicine. 16: 1-78. PMID 7783568 DOI: 10.1016/0098-2997(94)00040-A |
0.302 |
|
| 1993 |
List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1652-60. PMID 8102639 DOI: 10.1200/Jco.1993.11.9.1652 |
0.312 |
|
| 1991 |
Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood. 77: 348-54. PMID 1670760 DOI: 10.1182/Blood.V77.2.348.Bloodjournal772348 |
0.358 |
|
| 1989 |
Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood. 74: 1723-7. PMID 2790197 DOI: 10.1182/Blood.V74.5.1723.Bloodjournal7451723 |
0.314 |
|
| 1984 |
Johnson JM, Lemberger L, Novotny M, Forney RB, Dalton WS, Maskarinec MP. Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9-tetrahydrocannabinol in mice. Toxicology and Applied Pharmacology. 72: 440-8. PMID 6324414 DOI: 10.1016/0041-008X(84)90120-0 |
0.542 |
|
| 1979 |
Johnson JM, Lemberger L, Dalton WS, Forney RB. The effect of the acidic and basic fractions of marihuana whole smoke condensate on THC-induced hypothermia in mice Toxicology and Applied Pharmacology. 48: A42. |
0.51 |
|
| 1976 |
Dalton WS, Martz R, Rodda BE, Lemberger L, Forney RB. Influence of cannabidiol on secobarbital effects and plasma kinetics. Clinical Pharmacology and Therapeutics. 20: 695-700. PMID 791563 |
0.532 |
|
| 1976 |
Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clinical Pharmacology and Therapeutics. 19: 300-9. PMID 770048 |
0.538 |
|
| 1975 |
Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Effects of marihuana combined with secobarbital. Clinical Pharmacology and Therapeutics. 18: 298-304. PMID 1100299 |
0.522 |
|
| 1975 |
Dalton W, Martz R, Rodda B, Lemberger L, Forney R. Combined effects of Δ-9-THC and CBD in man Forensic Science. 5: 118. DOI: 10.1016/0300-9432(75)90280-0 |
0.511 |
|
| Show low-probability matches. |